SlideShare a Scribd company logo
1 of 35
Download to read offline
CURRENT STATUS OF
BIORESORBABLE SCAFFOLDS IN
THE TREATMENT OF CORONARY
ARTERY DISEASE
JACC DECEMBER 2014
INTRODUCTION
 DES are the most widely used stent platform
at present in interventional cardiology.
 DES overcame disadvantages such as acute
vessel recoil and dissection risk after POBA
and decreased M.I. and TLR rates compared
with BMS due to reduced neointimal tissue
growth.
Despite these some concerns remain:
The risk of late and very late stent thrombosis
Continued neointimal tissue growth and
neoatherosclerosis;
malapposition;
potential stent fracture
Incomplete endothelialization;
Vessel caging causing abnormal vasomotion.
 The next advance may be the introduction of
bioresorbable scaffolds (BRS). The term
scaffold highlights the temporary nature of a
BRS, distinct from a stent associated with a
permanent implant.
 First introduced in 1998 but forgotten due to
the success of BMS and, later, DES.
 With long-term data and the revelation of the
risks of metal stents, BRS development was
reinitiated, resulting in a variety of devices.
MATERIAL COMPOSITION AND
PROPERTIES
 The optimal BRS should ensure adequate
short- to mid-term scaffolding of the previously
stenosed vessel to avoid recoil and completely
dissolve afterward to prevent side effects.
 Thus, temporarily sufficient radial support is
needed, with struts as thin as possible.
 The optimal duration until full resorption is not
yet defined. To achieve these goals, a
considerable variety of materials and designs
are under investigation.
POLY L LACTIC ACID
 Most commonly used substrate.
 Most have strut thickness ~150μm but as low
as 100μm are under development
 Radial strength same as modern DES.
 Degradation by hydrolysis to lactic acid which
is metabolized into carbon dioxide and water.
 complete degradation achieved in 1 to 3 years
MAGNESIUM
 Superior radial strength.
 Earlier devices lacked the anti proliferative
drug.
 The electronegative charge that emerges
during the degradation of metal BRS is
antithrombotic.
 Degradation takes between 2 and 12 months.
 End products(corrosion) : inorganic salts.
 Offers 9 to 12 months of radial support.
 Advantage of having thinner struts due to high
tensile strength.
OTHER MATERIALS
 Tyrosine polycarbonate(experimental)
6 months of radial support
Resorption-24 and 36 months.
Final products of degradation are ethanol, water,
carbon dioxide
POTENTIAL BENEFITS
1. Multiple imaging analyses reveal beneficial
plaque stabilization and sealing caused by BRS-
induced remodeling although the clinical impact
needs further assessment.
2. Because BRS dissolve, this risk of length
induced thrombosis may be reduced.
3. Reduced neointimal tissue growth
,neoatherosclerosis and chronic inflammation
risks as reactions to a permanent metal implant
in DES. Because the BRS coating is degradable
stent thrombosis stimulus is absent.
4. One of the fascinating aspect is late lumen
enlargement in numerous patients with the Absorb
bioresorbable vascular scaffold (BVS) and DESolve
BRS observed by IVUS and OCT.
5. The initial mechanical flexibility of some BRS reduces
their influence on biomechanical properties and blood
flow.
6. Minor malapposition can be resolved by BRS self-
correction, and its degradation avoids long-term
malapposition.
7. Because there is no long-term vessel caging,
abnormal shear stress may be reduced, as seen with
FIRST BIORESORBABLE
SCAFFOLD
 The Igaki-Tamai stent
 Used in 1998
 PLLA-based BRS,160μm thick, self-
expandable when heated; consequently,
contrast dye at 80C is used for balloon
inflation. Expansion continues at body
temperature until dilation and vessel wall
resistance reach equilibrium.
 In 2000, Tamai et al. reported initial results
from 15 patients in whom 25 stents were
successfully implanted.
 During the first 6 months, minimal lumen diameter decreased
and then constantly increased to 2.22 ±0.56 mm at the 3-year
follow-up.
 IVUS analysis showed almost constant stent cross-sectional
area after 1, 2, and 3 years, whereas minimal lumen cross
sectional area decreased from 5.44 mm2 immediately after
the procedure to 3.64 mm2 after 6 months, then increased to
5.18 mm2 after 3 years.
 During the follow-up period, a total of 14 TLRs, 1 acute
scaffold thrombosis and 1 very late scaffold thrombosis, 1
lesion-related myocardial infarction, and 1 cardiac death were
noted.
 Accordingly, cumulative TLR rates per patient were 16% after
1 and 3 years, 18% after 5 years, and 28% after 10 year
Limitations:
Implantation requires an 8-French guiding
catheter.
The heated contrast dye may cause vessel wall
injury.
A new version of the device is currently
undergoing
CURRENTLY APPROVED
DEVICES
 Only 2 devices are CE certified:
1. Absorb Vascular Scaffold(BVS) (Abbott)
2. Desolve Scaffold (Elixir)
 No devices have U.S. Food and Drug
Administration approval.
 Tamai Stent is approved for peripheral
interventions only and not for coronary use.
Absorb Vascular Scaffold
 PLLA
 150μm thick strut which eludes 1:1 mixture of
PLLA and drug i.e. Everolimus.
 Full hydrolysis takes upto 3yrs.
 Although it demonstrated reduction in TLR but
decrease in stent minimal lumen diameter during
2 years of follow-up was also noted.
 Additional evaluation showed BVS shrinkage due
to acute recoil in quantitative coronary
angiography and late recoil in IVUS(ABSORB
COHORT A)
 This led to development of BVS1.1
 The struts were redesigned, leading to
increased radial strength and optimized drug
transfer.
 BVS strut thickness was unchanged, and
room-temperature BVS storage was now
possible.
 The ABSORB Cohort B studied BVS1.1
 During 2 years of follow-up, the overall MACE
rate was 9.0%. Late lumen loss in quantitative
coronary angiography was substantially lower
than in Cohort
 Remarkably, the mean lumen area also
decreased initially, but then increased
significantly 2 years after the index procedure.
 Vasomotion was tested by application of either
acetylcholine or methylergonovine and
subsequent lumen measurements, which
revealed restoration of pharmacologically
induced vasomotion 12 months after the
procedure.
 The other CE-approved, commercially
available (in Europe) BRS is the DESolve
scaffold, manufactured from PLLA and eluting
a mixture of anti-inflammatory myolimus and
PLLA.
 Strut thickness is 150 mm, and >95% of the
device is resorbed after 1 year.
 Its advantage,compared with other BRS, is a
wider range of expansion, with consequently
reduced strut fracture risk, and self-correction
of minor malapposition.
 During the 12-month follow-up period of the
multicenter DESolve first in humans trial, 1 TLR
occurred between 30 days and 6 months; there
were 2 other MACE events but no evidence of
scaffold thrombosis.
 The DESolve Nx study is currently investigating a
DESolve scaffold refinement, including elution of
antiproliferative novolimus and a larger device
size spectrum.
 A refined version, with 100-mm strut thickness,
will soon be available commercially.
 RCT comparing BRS with conventional DES
demonstrated a significantly lower rate of
definite very late stent thrombosis with the
bioresorbable polymer coating during a 4-year
follow-up.
 Additionally, improved vasomotion and
endothelialization was seen although hard
endpoints did not differ significantly.
SPECIAL CONSIDERATIONS
DIABETES MELLITUS
Data comparing BRS use in diabetic with
nondiabetic patients and diabetic patients who
underwent DES implantation found no significant
differences regarding the composite endpoint of
cardiac death, target vessel myocardial infarction,
and TLR at 1-year follow-up.
Diabetic patients have an increased repeat
revascularization risk due to diffuse diseased
vessels and a higher in-stent restenosis and stent
thrombosis risk.
Hence, from a long-term perspective, diabetic
patients might benefit from BRS rather than DES
LEFT MAIN STENTING
BRS use for LMCA was described but due to
larger LMCA diameters and limited availability of
BRS sizes and expansions its application at
present is limited for LM stenting.
INSTENT RESTENOSIS
Compared with drug-eluting balloons ,they
provide short-term scaffolding, ensure drug
delivery, and do not affect vessel diameter with
another metal layer, as with DES.
BRS strut thickness should be considered
while taking a decision in such cases.
CURRENT LIMITATIONS
 Absence of large RCTs
 Experience in complex cases
(bifurcation,ostial,cto) is limited and in such
cases IVUS should support BRS implantation.
 High strut thickness may lead to vessel injury,
nonlaminar flow, platelet deposition, and poor
deliverability
Calcification or tortuosity are technically
challenging.
Regardless of lesion anatomy, pre-dilation is
mandatory;direct stenting is not possible.
Predilatation makes the system prone for
dissection and ischemia.
 Only limited scaffold sizes are currently
available, and special facilities are needed for
storage of some.
 Due to these technical particularities, the total
cost and duration of PCI with a BRS may be
higher than with a conventional DES.
 Duration of DAPT with BRS is unclear.
 Current BRS limitations will likely be resolved
in the future. Although their advantages
already outnumber their disadvantages, large,
randomized, controlled trials are still needed.
CONCLUSIONS
 Although promising in certain conditions but
more randomised trials and technology
advance is required to implement them in a
wider perspective.
Bioabsorbable Scaffolds
Bioabsorbable Scaffolds

More Related Content

What's hot

DRUG ELUTING BALLOONS (DCB/DEB)
DRUG ELUTING BALLOONS (DCB/DEB)DRUG ELUTING BALLOONS (DCB/DEB)
DRUG ELUTING BALLOONS (DCB/DEB)Satyam Rajvanshi
 
Approch to bifurcation lesion
Approch to bifurcation lesionApproch to bifurcation lesion
Approch to bifurcation lesionRamachandra Barik
 
In stent retenosis pathophysiology
In stent retenosis pathophysiologyIn stent retenosis pathophysiology
In stent retenosis pathophysiologyNilesh Tawade
 
Stress echocardiography
Stress echocardiographyStress echocardiography
Stress echocardiographyFuad Farooq
 
Coronary artery dissection and perforation
Coronary artery dissection and perforationCoronary artery dissection and perforation
Coronary artery dissection and perforationFuad Farooq
 
Step by Step Rotational Athrectomy
Step by Step Rotational AthrectomyStep by Step Rotational Athrectomy
Step by Step Rotational AthrectomyDr Virbhan Balai
 
Tricuspid interventions
Tricuspid interventionsTricuspid interventions
Tricuspid interventionsdrsrb
 
In stent retenosis treatment
In stent retenosis treatmentIn stent retenosis treatment
In stent retenosis treatmentNilesh Tawade
 
InStent Resetenosis: An Algorithmic Approach to Diagnosis and Treatment
InStent Resetenosis:  An Algorithmic Approach to Diagnosis and TreatmentInStent Resetenosis:  An Algorithmic Approach to Diagnosis and Treatment
InStent Resetenosis: An Algorithmic Approach to Diagnosis and TreatmentNAJEEB ULLAH SOFI
 
Coronary artery dissection
Coronary artery dissectionCoronary artery dissection
Coronary artery dissectionAnirudh Allam
 
Longitudinal stent deformation in PCI
Longitudinal stent deformation in PCILongitudinal stent deformation in PCI
Longitudinal stent deformation in PCISatyam Rajvanshi
 

What's hot (20)

DRUG ELUTING BALLOONS (DCB/DEB)
DRUG ELUTING BALLOONS (DCB/DEB)DRUG ELUTING BALLOONS (DCB/DEB)
DRUG ELUTING BALLOONS (DCB/DEB)
 
Approch to bifurcation lesion
Approch to bifurcation lesionApproch to bifurcation lesion
Approch to bifurcation lesion
 
In stent retenosis pathophysiology
In stent retenosis pathophysiologyIn stent retenosis pathophysiology
In stent retenosis pathophysiology
 
How to do dk crush
How to do dk crushHow to do dk crush
How to do dk crush
 
Bifurcation stentig
Bifurcation stentigBifurcation stentig
Bifurcation stentig
 
Stress echocardiography
Stress echocardiographyStress echocardiography
Stress echocardiography
 
Coronary artery dissection and perforation
Coronary artery dissection and perforationCoronary artery dissection and perforation
Coronary artery dissection and perforation
 
Left main pci
Left main pciLeft main pci
Left main pci
 
Drug eluting stent
Drug eluting stentDrug eluting stent
Drug eluting stent
 
Step by Step Rotational Athrectomy
Step by Step Rotational AthrectomyStep by Step Rotational Athrectomy
Step by Step Rotational Athrectomy
 
Tricuspid interventions
Tricuspid interventionsTricuspid interventions
Tricuspid interventions
 
Chronic total occlusion
Chronic total occlusionChronic total occlusion
Chronic total occlusion
 
In stent retenosis treatment
In stent retenosis treatmentIn stent retenosis treatment
In stent retenosis treatment
 
Different Coronary stent design PPT
Different Coronary stent design PPTDifferent Coronary stent design PPT
Different Coronary stent design PPT
 
Stents3
Stents3Stents3
Stents3
 
InStent Resetenosis: An Algorithmic Approach to Diagnosis and Treatment
InStent Resetenosis:  An Algorithmic Approach to Diagnosis and TreatmentInStent Resetenosis:  An Algorithmic Approach to Diagnosis and Treatment
InStent Resetenosis: An Algorithmic Approach to Diagnosis and Treatment
 
Coronary artery dissection
Coronary artery dissectionCoronary artery dissection
Coronary artery dissection
 
Asd device closure
Asd device closureAsd device closure
Asd device closure
 
Coronary air embolism
Coronary air embolismCoronary air embolism
Coronary air embolism
 
Longitudinal stent deformation in PCI
Longitudinal stent deformation in PCILongitudinal stent deformation in PCI
Longitudinal stent deformation in PCI
 

Similar to Bioabsorbable Scaffolds

Journal club drug eluting balloon for cad
Journal club   drug eluting balloon for cadJournal club   drug eluting balloon for cad
Journal club drug eluting balloon for cadKunal Mahajan
 
isr presentation.pptx
isr presentation.pptxisr presentation.pptx
isr presentation.pptxnetnannyy
 
isr presentation.pptx
isr presentation.pptxisr presentation.pptx
isr presentation.pptxnetnannyy
 
Coronary Calcium Modification
Coronary Calcium ModificationCoronary Calcium Modification
Coronary Calcium ModificationNAJEEB ULLAH SOFI
 
Myocardial Infarction, Atherosclerosis and The treatments
Myocardial Infarction, Atherosclerosis and The treatments Myocardial Infarction, Atherosclerosis and The treatments
Myocardial Infarction, Atherosclerosis and The treatments Seyed Mohammad Zargar
 
Endovascularbrachytherapy
EndovascularbrachytherapyEndovascularbrachytherapy
EndovascularbrachytherapyParag Roy
 
Problem associated with drug eluting stent
Problem associated with drug eluting stentProblem associated with drug eluting stent
Problem associated with drug eluting stentPRAVEEN GUPTA
 
Tissue engineering of stents
Tissue engineering of stentsTissue engineering of stents
Tissue engineering of stentsDr. sreeremya S
 
In stent neoatherosclerosis
In stent neoatherosclerosis In stent neoatherosclerosis
In stent neoatherosclerosis Kunal Mahajan
 
1362573078 dr. rajdeep agrawal
1362573078 dr. rajdeep agrawal1362573078 dr. rajdeep agrawal
1362573078 dr. rajdeep agrawaldfsimedia
 
Coronarystents phpapp02
Coronarystents phpapp02Coronarystents phpapp02
Coronarystents phpapp02Saurabh Gupta
 
Bifurcation lesions
Bifurcation lesionsBifurcation lesions
Bifurcation lesionsManjunath D
 

Similar to Bioabsorbable Scaffolds (20)

Drug Coated Balloons.pptx
Drug Coated Balloons.pptxDrug Coated Balloons.pptx
Drug Coated Balloons.pptx
 
CORONARY STENTS.pptx
CORONARY STENTS.pptxCORONARY STENTS.pptx
CORONARY STENTS.pptx
 
Journal club drug eluting balloon for cad
Journal club   drug eluting balloon for cadJournal club   drug eluting balloon for cad
Journal club drug eluting balloon for cad
 
Biovascular scaffolds
Biovascular scaffolds Biovascular scaffolds
Biovascular scaffolds
 
BVS IN STEMI
BVS IN STEMIBVS IN STEMI
BVS IN STEMI
 
Bio vascular scaffold i tammi raju
Bio vascular scaffold i tammi rajuBio vascular scaffold i tammi raju
Bio vascular scaffold i tammi raju
 
Bio vascular scaffold i tammi raju
Bio vascular scaffold i tammi rajuBio vascular scaffold i tammi raju
Bio vascular scaffold i tammi raju
 
isr presentation.pptx
isr presentation.pptxisr presentation.pptx
isr presentation.pptx
 
isr presentation.pptx
isr presentation.pptxisr presentation.pptx
isr presentation.pptx
 
Coronary Calcium Modification
Coronary Calcium ModificationCoronary Calcium Modification
Coronary Calcium Modification
 
Myocardial Infarction, Atherosclerosis and The treatments
Myocardial Infarction, Atherosclerosis and The treatments Myocardial Infarction, Atherosclerosis and The treatments
Myocardial Infarction, Atherosclerosis and The treatments
 
Biosolve II
Biosolve IIBiosolve II
Biosolve II
 
Endovascularbrachytherapy
EndovascularbrachytherapyEndovascularbrachytherapy
Endovascularbrachytherapy
 
Problem associated with drug eluting stent
Problem associated with drug eluting stentProblem associated with drug eluting stent
Problem associated with drug eluting stent
 
Tissue engineering of stents
Tissue engineering of stentsTissue engineering of stents
Tissue engineering of stents
 
In stent neoatherosclerosis
In stent neoatherosclerosis In stent neoatherosclerosis
In stent neoatherosclerosis
 
1362573078 dr. rajdeep agrawal
1362573078 dr. rajdeep agrawal1362573078 dr. rajdeep agrawal
1362573078 dr. rajdeep agrawal
 
Coronarystents phpapp02
Coronarystents phpapp02Coronarystents phpapp02
Coronarystents phpapp02
 
Cardiac Stents
Cardiac StentsCardiac Stents
Cardiac Stents
 
Bifurcation lesions
Bifurcation lesionsBifurcation lesions
Bifurcation lesions
 

Recently uploaded

SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
Shock Continuum - Sara Crager - TBS24.pdf
Shock Continuum - Sara Crager - TBS24.pdfShock Continuum - Sara Crager - TBS24.pdf
Shock Continuum - Sara Crager - TBS24.pdfscanFOAM
 
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptx
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptxIntroduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptx
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptxspmdoc
 
liver, Biliary, & pancreatic secretions.pptx
liver, Biliary, & pancreatic  secretions.pptxliver, Biliary, & pancreatic  secretions.pptx
liver, Biliary, & pancreatic secretions.pptxDr.Nusrat Tariq
 
Common Infections Affecting The Human Body
Common Infections Affecting The Human BodyCommon Infections Affecting The Human Body
Common Infections Affecting The Human Bodyafshanshabil
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSapna Thakur
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
Rheumatoid arthritis - Musculoskeletal disorders.ppt
Rheumatoid arthritis - Musculoskeletal disorders.pptRheumatoid arthritis - Musculoskeletal disorders.ppt
Rheumatoid arthritis - Musculoskeletal disorders.pptraviapr7
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxprincebieber28
 
Hip Joint Biomechanics & its Kinetics and Kinematics
Hip Joint Biomechanics & its Kinetics and KinematicsHip Joint Biomechanics & its Kinetics and Kinematics
Hip Joint Biomechanics & its Kinetics and KinematicsRishiRajgude
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxraviapr7
 
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and Oculomics
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and OculomicsNext Gen Ophthalmic Imaging for Neurodegenerative Diseases and Oculomics
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and OculomicsPetteriTeikariPhD
 
M.PHARM PHARMACEUTICS DDS - Question Bank
M.PHARM PHARMACEUTICS  DDS - Question BankM.PHARM PHARMACEUTICS  DDS - Question Bank
M.PHARM PHARMACEUTICS DDS - Question BankSumathi Arumugam
 
Heme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxHeme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxRajendra Dev Bhatt
 
Systemic Lupus Erythematosus -SLE PT2.ppt
Systemic  Lupus  Erythematosus -SLE PT2.pptSystemic  Lupus  Erythematosus -SLE PT2.ppt
Systemic Lupus Erythematosus -SLE PT2.pptraviapr7
 
प्रसव.pptx labour and it's stages and mechanism of labour
प्रसव.pptx labour and it's stages and mechanism of labourप्रसव.pptx labour and it's stages and mechanism of labour
प्रसव.pptx labour and it's stages and mechanism of labourjaimahakal2305
 
hema-2-reviewer (1).pdf Hematology Reviewer
hema-2-reviewer (1).pdf Hematology Reviewerhema-2-reviewer (1).pdf Hematology Reviewer
hema-2-reviewer (1).pdf Hematology ReviewerANGELOMSARABIA
 
Dissociative and Conversion Disorder and its associated types
Dissociative and Conversion Disorder and its associated typesDissociative and Conversion Disorder and its associated types
Dissociative and Conversion Disorder and its associated typesProf. (Dr.) Rahul Sharma
 

Recently uploaded (20)

SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
Shock Continuum - Sara Crager - TBS24.pdf
Shock Continuum - Sara Crager - TBS24.pdfShock Continuum - Sara Crager - TBS24.pdf
Shock Continuum - Sara Crager - TBS24.pdf
 
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptx
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptxIntroduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptx
Introduction-to-Host-Defenses-in-Infectious-Disease-Epidemiology.pptx
 
liver, Biliary, & pancreatic secretions.pptx
liver, Biliary, & pancreatic  secretions.pptxliver, Biliary, & pancreatic  secretions.pptx
liver, Biliary, & pancreatic secretions.pptx
 
Common Infections Affecting The Human Body
Common Infections Affecting The Human BodyCommon Infections Affecting The Human Body
Common Infections Affecting The Human Body
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
 
Pain.pptx
Pain.pptxPain.pptx
Pain.pptx
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
Rheumatoid arthritis - Musculoskeletal disorders.ppt
Rheumatoid arthritis - Musculoskeletal disorders.pptRheumatoid arthritis - Musculoskeletal disorders.ppt
Rheumatoid arthritis - Musculoskeletal disorders.ppt
 
Shock .pptx
Shock .pptxShock .pptx
Shock .pptx
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptx
 
Hip Joint Biomechanics & its Kinetics and Kinematics
Hip Joint Biomechanics & its Kinetics and KinematicsHip Joint Biomechanics & its Kinetics and Kinematics
Hip Joint Biomechanics & its Kinetics and Kinematics
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptx
 
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and Oculomics
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and OculomicsNext Gen Ophthalmic Imaging for Neurodegenerative Diseases and Oculomics
Next Gen Ophthalmic Imaging for Neurodegenerative Diseases and Oculomics
 
M.PHARM PHARMACEUTICS DDS - Question Bank
M.PHARM PHARMACEUTICS  DDS - Question BankM.PHARM PHARMACEUTICS  DDS - Question Bank
M.PHARM PHARMACEUTICS DDS - Question Bank
 
Heme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxHeme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptx
 
Systemic Lupus Erythematosus -SLE PT2.ppt
Systemic  Lupus  Erythematosus -SLE PT2.pptSystemic  Lupus  Erythematosus -SLE PT2.ppt
Systemic Lupus Erythematosus -SLE PT2.ppt
 
प्रसव.pptx labour and it's stages and mechanism of labour
प्रसव.pptx labour and it's stages and mechanism of labourप्रसव.pptx labour and it's stages and mechanism of labour
प्रसव.pptx labour and it's stages and mechanism of labour
 
hema-2-reviewer (1).pdf Hematology Reviewer
hema-2-reviewer (1).pdf Hematology Reviewerhema-2-reviewer (1).pdf Hematology Reviewer
hema-2-reviewer (1).pdf Hematology Reviewer
 
Dissociative and Conversion Disorder and its associated types
Dissociative and Conversion Disorder and its associated typesDissociative and Conversion Disorder and its associated types
Dissociative and Conversion Disorder and its associated types
 

Bioabsorbable Scaffolds

  • 1. CURRENT STATUS OF BIORESORBABLE SCAFFOLDS IN THE TREATMENT OF CORONARY ARTERY DISEASE JACC DECEMBER 2014
  • 2. INTRODUCTION  DES are the most widely used stent platform at present in interventional cardiology.  DES overcame disadvantages such as acute vessel recoil and dissection risk after POBA and decreased M.I. and TLR rates compared with BMS due to reduced neointimal tissue growth.
  • 3. Despite these some concerns remain: The risk of late and very late stent thrombosis Continued neointimal tissue growth and neoatherosclerosis; malapposition; potential stent fracture Incomplete endothelialization; Vessel caging causing abnormal vasomotion.
  • 4.  The next advance may be the introduction of bioresorbable scaffolds (BRS). The term scaffold highlights the temporary nature of a BRS, distinct from a stent associated with a permanent implant.
  • 5.  First introduced in 1998 but forgotten due to the success of BMS and, later, DES.  With long-term data and the revelation of the risks of metal stents, BRS development was reinitiated, resulting in a variety of devices.
  • 6. MATERIAL COMPOSITION AND PROPERTIES  The optimal BRS should ensure adequate short- to mid-term scaffolding of the previously stenosed vessel to avoid recoil and completely dissolve afterward to prevent side effects.  Thus, temporarily sufficient radial support is needed, with struts as thin as possible.  The optimal duration until full resorption is not yet defined. To achieve these goals, a considerable variety of materials and designs are under investigation.
  • 7. POLY L LACTIC ACID  Most commonly used substrate.  Most have strut thickness ~150μm but as low as 100μm are under development  Radial strength same as modern DES.  Degradation by hydrolysis to lactic acid which is metabolized into carbon dioxide and water.  complete degradation achieved in 1 to 3 years
  • 8. MAGNESIUM  Superior radial strength.  Earlier devices lacked the anti proliferative drug.  The electronegative charge that emerges during the degradation of metal BRS is antithrombotic.  Degradation takes between 2 and 12 months.  End products(corrosion) : inorganic salts.  Offers 9 to 12 months of radial support.  Advantage of having thinner struts due to high tensile strength.
  • 9. OTHER MATERIALS  Tyrosine polycarbonate(experimental) 6 months of radial support Resorption-24 and 36 months. Final products of degradation are ethanol, water, carbon dioxide
  • 10.
  • 11.
  • 12. POTENTIAL BENEFITS 1. Multiple imaging analyses reveal beneficial plaque stabilization and sealing caused by BRS- induced remodeling although the clinical impact needs further assessment. 2. Because BRS dissolve, this risk of length induced thrombosis may be reduced. 3. Reduced neointimal tissue growth ,neoatherosclerosis and chronic inflammation risks as reactions to a permanent metal implant in DES. Because the BRS coating is degradable stent thrombosis stimulus is absent.
  • 13. 4. One of the fascinating aspect is late lumen enlargement in numerous patients with the Absorb bioresorbable vascular scaffold (BVS) and DESolve BRS observed by IVUS and OCT. 5. The initial mechanical flexibility of some BRS reduces their influence on biomechanical properties and blood flow. 6. Minor malapposition can be resolved by BRS self- correction, and its degradation avoids long-term malapposition. 7. Because there is no long-term vessel caging, abnormal shear stress may be reduced, as seen with
  • 14. FIRST BIORESORBABLE SCAFFOLD  The Igaki-Tamai stent  Used in 1998  PLLA-based BRS,160μm thick, self- expandable when heated; consequently, contrast dye at 80C is used for balloon inflation. Expansion continues at body temperature until dilation and vessel wall resistance reach equilibrium.  In 2000, Tamai et al. reported initial results from 15 patients in whom 25 stents were successfully implanted.
  • 15.  During the first 6 months, minimal lumen diameter decreased and then constantly increased to 2.22 ±0.56 mm at the 3-year follow-up.  IVUS analysis showed almost constant stent cross-sectional area after 1, 2, and 3 years, whereas minimal lumen cross sectional area decreased from 5.44 mm2 immediately after the procedure to 3.64 mm2 after 6 months, then increased to 5.18 mm2 after 3 years.  During the follow-up period, a total of 14 TLRs, 1 acute scaffold thrombosis and 1 very late scaffold thrombosis, 1 lesion-related myocardial infarction, and 1 cardiac death were noted.  Accordingly, cumulative TLR rates per patient were 16% after 1 and 3 years, 18% after 5 years, and 28% after 10 year
  • 16. Limitations: Implantation requires an 8-French guiding catheter. The heated contrast dye may cause vessel wall injury. A new version of the device is currently undergoing
  • 17.
  • 18. CURRENTLY APPROVED DEVICES  Only 2 devices are CE certified: 1. Absorb Vascular Scaffold(BVS) (Abbott) 2. Desolve Scaffold (Elixir)  No devices have U.S. Food and Drug Administration approval.  Tamai Stent is approved for peripheral interventions only and not for coronary use.
  • 19. Absorb Vascular Scaffold  PLLA  150μm thick strut which eludes 1:1 mixture of PLLA and drug i.e. Everolimus.  Full hydrolysis takes upto 3yrs.  Although it demonstrated reduction in TLR but decrease in stent minimal lumen diameter during 2 years of follow-up was also noted.  Additional evaluation showed BVS shrinkage due to acute recoil in quantitative coronary angiography and late recoil in IVUS(ABSORB COHORT A)
  • 20.  This led to development of BVS1.1  The struts were redesigned, leading to increased radial strength and optimized drug transfer.  BVS strut thickness was unchanged, and room-temperature BVS storage was now possible.
  • 21.  The ABSORB Cohort B studied BVS1.1  During 2 years of follow-up, the overall MACE rate was 9.0%. Late lumen loss in quantitative coronary angiography was substantially lower than in Cohort  Remarkably, the mean lumen area also decreased initially, but then increased significantly 2 years after the index procedure.
  • 22.  Vasomotion was tested by application of either acetylcholine or methylergonovine and subsequent lumen measurements, which revealed restoration of pharmacologically induced vasomotion 12 months after the procedure.
  • 23.  The other CE-approved, commercially available (in Europe) BRS is the DESolve scaffold, manufactured from PLLA and eluting a mixture of anti-inflammatory myolimus and PLLA.  Strut thickness is 150 mm, and >95% of the device is resorbed after 1 year.  Its advantage,compared with other BRS, is a wider range of expansion, with consequently reduced strut fracture risk, and self-correction of minor malapposition.
  • 24.  During the 12-month follow-up period of the multicenter DESolve first in humans trial, 1 TLR occurred between 30 days and 6 months; there were 2 other MACE events but no evidence of scaffold thrombosis.  The DESolve Nx study is currently investigating a DESolve scaffold refinement, including elution of antiproliferative novolimus and a larger device size spectrum.  A refined version, with 100-mm strut thickness, will soon be available commercially.
  • 25.  RCT comparing BRS with conventional DES demonstrated a significantly lower rate of definite very late stent thrombosis with the bioresorbable polymer coating during a 4-year follow-up.  Additionally, improved vasomotion and endothelialization was seen although hard endpoints did not differ significantly.
  • 26. SPECIAL CONSIDERATIONS DIABETES MELLITUS Data comparing BRS use in diabetic with nondiabetic patients and diabetic patients who underwent DES implantation found no significant differences regarding the composite endpoint of cardiac death, target vessel myocardial infarction, and TLR at 1-year follow-up. Diabetic patients have an increased repeat revascularization risk due to diffuse diseased vessels and a higher in-stent restenosis and stent thrombosis risk. Hence, from a long-term perspective, diabetic patients might benefit from BRS rather than DES
  • 27. LEFT MAIN STENTING BRS use for LMCA was described but due to larger LMCA diameters and limited availability of BRS sizes and expansions its application at present is limited for LM stenting.
  • 28. INSTENT RESTENOSIS Compared with drug-eluting balloons ,they provide short-term scaffolding, ensure drug delivery, and do not affect vessel diameter with another metal layer, as with DES. BRS strut thickness should be considered while taking a decision in such cases.
  • 29. CURRENT LIMITATIONS  Absence of large RCTs  Experience in complex cases (bifurcation,ostial,cto) is limited and in such cases IVUS should support BRS implantation.  High strut thickness may lead to vessel injury, nonlaminar flow, platelet deposition, and poor deliverability
  • 30. Calcification or tortuosity are technically challenging. Regardless of lesion anatomy, pre-dilation is mandatory;direct stenting is not possible. Predilatation makes the system prone for dissection and ischemia.
  • 31.  Only limited scaffold sizes are currently available, and special facilities are needed for storage of some.  Due to these technical particularities, the total cost and duration of PCI with a BRS may be higher than with a conventional DES.  Duration of DAPT with BRS is unclear.
  • 32.  Current BRS limitations will likely be resolved in the future. Although their advantages already outnumber their disadvantages, large, randomized, controlled trials are still needed.
  • 33. CONCLUSIONS  Although promising in certain conditions but more randomised trials and technology advance is required to implement them in a wider perspective.